EU assesses GSK-Vir COVID-19 antibody therapy for authorisation

EU assessing GSK-Vir monoclonal antibody for COVID-19 treatment
EU assessing GSK-Vir monoclonal antibody for COVID-19 treatment Copyright Thomson Reuters 2021
By Reuters
Share this articleComments
Share this articleClose Button

-European health regulator said https://www.ema.europa.eu/en/news/ema-receives-application-marketing-authorisation-xevudy-sotrovimab-treating-patients-covid-19 on Thursday it was assessing a marketing authorisation application for GSK-Vir Biotechnology's monoclonal antibody treatment for COVID-19 and could give its opinion within two months.

The drug, sotrovimab, branded as Xevudy was already under a speedy review by the European Medicines Agency (EMA), and GSK's application makes the drug the fourth application currently under EU lenses for the treatment of COVID-19.

The drug is authorised for emergency use in the United States to prevent mild or moderate cases of COVID-19 from worsening. The EMA has given its go-ahead for use by member states but Thursday's application would count for an EU-wide approval, if recommended by the EMA.

Unlike oral options from Merck and Pfizer, sotrovimab is given via an infusion. Sotrovimab belongs to a class of drugs known as monoclonal antibodies that are lab-generated compounds mimicking the body's natural defences.

However, last week GSK and Vir said a study showed the antibody treatment would work when given as a shot in the arm as well, potentially offering more convenience.

The EMA recently backed similar antibody therapies from American-Swiss partners Regeneron-Roche and another from South Korea's Celltrion, as the region builds up its defence against surging cases.

Share this articleComments

You might also like

Mass brawl breaks out in Georgian parliament over controversial media law

Ukraine war: Blinken assure Black Sea allies of US support, Russian strikes hit Donbas and Kherson

An Arab-Israel axis against the Islamic Republic of Iran is now a reality